The approval extends the use of RYALTRIS, a fixed-dose combination of olopatadine hydrochloride and mometasone furoate, to a younger paediatric population. The therapy is now approved in the US for adults and children aged six years and older.
The approval extends the use of RYALTRIS, a fixed-dose combination of olopatadine hydrochloride and mometasone furoate, to a younger paediatric population. The therapy is now approved in the US for adults and children aged six years and older.